Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy

Company Overview - Kodiak Sciences is a clinical-stage biotechnology company focused on innovative therapies for retinal diseases [6] - The company has a market capitalization of $1.6 billion and a net income of -$217.34 million [4] - As of February 23, 2026, the share price was $25.91, reflecting a 480% increase over the past year, significantly outperforming the S&P 500's 13% gain [7] Recent Developments - On February 17, 2026, Baker Bros. Advisors LP disclosed the purchase of 2,608,696 shares of Kodiak Sciences, valued at approximately $53.42 million [1][2] - The value of Kodiak Sciences' holdings increased by $273.57 million at the end of the fourth quarter of 2025, accounting for both the additional shares and stock price movement [2] Product Pipeline - Kodiak's lead product candidate, KSI-301, is in Phase IIb/III trials targeting wet age-related macular degeneration and other retinal disorders [8] - The company is also advancing KSI-101 in the PEAK and PINNACLE studies for retinopathy, targeting a segment within the $15 billion anti-VEGF marketplace [9] Financial Performance - In the third quarter, Kodiak Sciences reported R&D spending of $50.5 million and a net loss of $61.5 million [9] - The company had cash reserves of $72 million as of September 30, 2025, prior to a $184 million capital raise in December [9] Investment Implications - Kodiak Sciences represents 3.26% of Baker Bros. Advisors LP's 13F reportable assets under management (AUM) after the recent trade [7] - The company's future performance hinges on the success of its Phase 3 trials, which could position it competitively in the retinal vascular disease market [10]